One hundred and fifteen patients, separated into 4 groups, received neostigmine 5 mg with either atropine 1.2 mg or 1.8 mg, or glycopyrrolate 0.6 mg or 0.9 mg. Those receiving 0.9mg glycopyrrolate had insignificant changes in heart rate in the immediate postreversal period. It is recommended that when glycopyrrolate is used with 5mg neostigmine, the optimum dose is 0.9 mg.
Introduction
In 1942, an extract of curare (Intocostrin) was reported to be a safe muscle relaxant in 25 patients when administered in doses of 80-100mg of active curare substance'. Subsequently many reports were published substantiating the role of curare and its active constituent, tubocurarine chloride, in anaesthetic practice2'. In Liverpool, a tradition of using large (maximum 45 mg) doses of tubocurarine chloride was established by the pioneering work of Gray6.
Reversal of the effects of curare by the use of the anticholinesterase, physostigmine, was reported as early as 19007. However, it was not until the synthesis by Aeschlimann and Reinhert in 19318 of the quaternary ammonium anticholinesterase, neostigmine methylsulphate (Prostigmin), that an alternative became available. This agent was used first in 1931 to treat paralytic ileus9, and later in 1932 Remen'0 and in 1935 Walker1' reported its use in the symptomatic treatment of myasthenia gravis. Although scientific evidence for the superiority of neostigmine over physostigmine was not obtained in animals until 194412 and confirmed in 1948 '3, Griffith and Johnson' in 1942 demonstrated in man that neostigmine would reverse residual neuromuscular block produced by curare.
The optimum dose of neostigmine to be used for reversal of residual neuromuscular block is debatable. Based on his clinical judgment, Gray'4 recommended doses of 3-5 mg to reverse partial curarization. Bridenbaugh and Churchill-Davidson'" also suggested that doses of up to 5mg neostigmine were advisable to restore neuromuscular function. They further suggested that these doses would reverse neuromuscular block when given only a few minutes after the administration of a non-depolarizing muscle relaxant, provided that the degree of block was judged clinically not to be excessive. It was the so-called 'Liverpool School' of anaesthesia which advocated the regular use of large doses of neostigmine (5 mg), since it was they who popularized the use of tubocurarine in large doses (45 mg). This philosophy was confirmed in 1979 by Viby-Mogensen et al.'6 who also suggested that doses in excess of the 'standard' 2.5 mg neostigmine were necessary for adequate clinical reversal of neuromuscular block in 40% of their patients.
The use of anticholinergics with anticholinesterases is mandatory in order to protect the patient from the peripheral muscarinic effects of these agents. Atropine is the most commonly used anticholinergic, but in recent years the quaternary agent, glycopyrrolate, has been extensively evaluated and has been shown to possess some advantages over atropine'7. Specifically, the initial tachycardia and subsequent bradycardia are less, and better control of oropharyngeal secretions is produced'8.
Most of the published studies where glycopyrrolate was used in a mixture with neostigmine have used doses of neostigmine of 2.5 mg'9, or 50 gg/kg body weight20. For an excellent review on glycopyrrolate see Mirakhur and Dundee2".
There have been no previous reports on the use of glycopyrrolate with doses of neostigmine as large as 5 mg. The present study evaluated the optimum dose of glycopyrrolate and atropine as anticholinergic agents when used with neostigmine in this dosage.
Methods
The study was carried out in patients undergoing general surgical operations in which anaesthesia involved the use of a non-depolarizing muscle relaxant. Informed consent was obtained from each patient prior to entry into the study.
Exclusion criteria were any condition in which it would be inadvisable to reverse residual neuromuscular block, known hypersensitivity to either atropine or glycopyrrolate, concomitant medication which might affect the cardiovascular system, and the use of intraoperative anticholinergics.
Patients were premedicated with diazepam 10 mg orally two hours preoperatively. Anaesthesia was induced with thiopentone 3-5 mg/kg and fentanyl 3-5,ug/kg. Tracheal intubation was performed after administration of the non-depolarizing muscle relaxant, pancuronium, in a dose of 0.1 mg/kg. Anaesthesia was maintained with 70% nitrous oxide in oxygen and increments of fentanyl and pancuronium as needed. Intermittent positive pressure ventilation was maintained during the operation using an East-Radcliffe ventilator.
At the end of surgery and with the patients breathing a 50% nitrous oxide in oxygen mixture, a mixture of neostigmine methyl sulphate 5.0 mg with the 'study drug' was administered as a 'bolus' 0141-0768/86/ 010019-03/$02.00/0 0 1986
The Royal Society of Medicine intravenously. This was either atropine 1.2 mg or 1.8 mg, or glycopyrrolate 0.6 mg or 0.9 mg. The anticholinergic component of the reversal mixture was administered in a double-blind manner and allocation to each of the four study groups was on a random basis. When adequate spontaneous ventilation was established, the patients were extubated and oxygen was given via an anaesthetic mask. The patients were studied in the operating theatre for ten minutes after the administration of the reversal mixture, following which they were transferred to the recovery area. ECG was monitored continuously, and heart rate recorded at the following times relative to the administration of the reversal mixture, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 55, 70, 85, 110 minutes. Oropharyngeal secretions were assessed by the anaesthetist as being 'excessive' or 'acceptable' at the time of extubation. Data were recorded on specially designed forms. If any patient required atropine during the period of observation, the data following the time of its administration were excluded.
Heart rate data were analysed 'within' groups by a two-way analysis of variance and 'between' groups using a non-paired t test. Non parametric data were analysed using Fisher's exact test. Statistical significance was taken as a P value of less than 0.05. ,,
Results
One hundred and fifteen patients were entered into the study. The number in each of the four study groups, their physical characteristics, heart rate before administration of the reversal mixtures, doses of pancuronium and fentanyl administered are shown in Table 1 . The groups were well matched in every respect, apart from a lower heart rate before reversal in the group receiving glycopyrrolate 0.9mg. The mean change in heart rates in the 110 minutes following administration of the reversal mixtures is shown in Figure 1A . Mean heart rate fell in all the four groups of patients, the magnitude of the fall being less in those patients receiving the higher doses of each anticholinergic drug. Patients who received atropine 1.8 mg showed an initial and statistically significant (P<0.01) rise in heart rate. This was not observed with any of the other three groups.
The change in heart rate in the first ten minutes after the administration of the reversal mixtures is shown in Figure 1B . Two-way analysis of variance indicated that there were statistically significant changes (P< 0.005, using the method of Greenhouse and Geisser22) in heart rate in every group, except that receiving glycopyrrolate 0.9 mg.
Seventeen patients receiving atropine had 'excessive' oropharyngeal secretions as opposed to 11 receiving glycopyrrolate. This difference, however, was not statistically significant.
Discussion
The present study was initiated because of the lack of data on the optimum adult dose of glycopyrrolate or atropine to be used with 5 mg neostigmine. It has confirmed that best control of the effects of neostigmine is obtained by the use of 1.8 mg atropine, although this dose did produce an initial rise in heart rate. However, the only patients who did not show any statistically significant change in heart rate in the immediate postreversal period were those receiving glycopyrrolate 0.9 mg.
Neostigmine has a dose-dependent duration of action: Blitt et al. 23 showed that a dose of approximately 2 mg lasted 116 minutes, whereas a dose of approximately 4 mg had a duration of greater than 3 hours. This latter exceeds the duration of action a. of atropine and thus patients may develop postreversal bradycardia. Glycopyrrolate has a duration of action significantly greater than that of atropine20, and thus when large doses of neostigmine are used glycopyrrolate would appear to be a superior alternative to atropine.
Glycopyrrolate, being a quaternary ammonium compound, does not penetrate the blood-brain barrier24, and recent studies have shown that post-anaesthetic arousal is more rapid when glycopyrrolate, rather than atropine, is used25.
In conclusion, when neostigmine in a dose of 5 mg is used to reverse residual non-depolarizing neuromuscular blockade, the optimum dose of glycopyrrolate is 0.9 mg. This dose is associated with insignificant changes in heart rate.
